{"id":"W2547646848","doi":"10.1016/j.rmed.2016.11.001","title":"Rationale and study design of RESPITE: An open-label, phase 3b study of riociguat in patients with pulmonary arterial hypertension who demonstrate an insufficient response to treatment with phosphodiesterase-5 inhibitors","year":2016,"lang":"en","type":"article","venue":"Respiratory Medicine","topic":"Pulmonary Hypertension Research and Treatments","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"Bayer HealthCare; United Therapeutics Corporation; Gilead Sciences; GlaxoSmithKline; Pfizer; Ikaria; Eli Lilly and Company","keywords":"Riociguat; Medicine; Sildenafil; cGMP-specific phosphodiesterase type 5; Cyclic guanosine monophosphate; Internal medicine; Pulmonary hypertension; Tadalafil; Cardiology; Chronic thromboembolic pulmonary hypertension; Nitric oxide","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0544165,0.005707663,0.007497788,0.001845833,0.003778167,0.003417401,0.003460033,0.005532147,0.01208825],"category_scores_gemma":[0.02484975,0.004515855,0.003789626,0.001471614,0.007493336,0.002589368,0.001701843,0.007949967,0.004744168],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002169814,"about_ca_system_score_gemma":0.009711306,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009897872,"about_ca_topic_score_gemma":0.002342723,"domain_scores_codex":[0.9758011,0.01609069,0.001926098,0.002753838,0.002241716,0.00118651],"domain_scores_gemma":[0.9909447,0.003270186,0.001306421,0.001336551,0.001124916,0.002017131],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7893122,0.02964024,0.01501526,0.01283117,0.00411581,0.001416269,0.001504086,0.004413689,0.01613243,0.0284742,0.01606344,0.0810812],"study_design_scores_gemma":[0.7310966,0.1257451,0.01975926,0.003396024,0.004292895,0.001157136,0.0005370532,0.006904497,0.005016493,0.016443,0.08521378,0.0004381115],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"protocol","genre_gemma":"protocol","genre_scores_codex":[0.06558869,0.00813146,0.02722112,0.005273683,0.003622001,0.8774231,0.005270672,0.0003243534,0.007144871],"genre_scores_gemma":[0.1172142,0.002417089,0.04961637,0.007794439,0.001446187,0.8167565,0.00178533,0.00008409609,0.002885815],"genre_candidate":"protocol","genre_consensus":"protocol","teacher_disagreement_score":0.0544165,"threshold_uncertainty_score":0.2877854,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0877483271850614,"score_gpt":0.3468517795948621,"score_spread":0.2591034524098007,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}